Thomas Byrne

Tom Byrne is the President of Byrne Investment Research (BIR), which provides fundamental, bottom-up equity research on micro-cap and small-cap companies. BIR looks for monopolistic companies using quantitative and qualitative analysis across every industry, but the emphasis is on technology, engineering, healthcare, and medical devices. Prior to starting his own firm in 1998, Mr. Byrne spent five years as Director of Research for Individual Investor Group, publisher of Individual Investor magazine, Ticker magazine, the SSR newsletter and the Individual Investor website. In 1997, Mr. Byrne created the America’s Fastest Growing Companies Index, the first index to track small-cap growth companies. Prior to joining Individual Investor Group, Mr. Byrne was invited to become the first small-cap equity analyst at Standard & Poor’s, from 1989 to 1993. Mr. Byrne helped create the S&P SmallCap 600 Index and the S&P 500 Spyder (SPY), the first public exchange traded fund (ETF). Mr. Byrne was also the first analyst to publish small cap research in the S&P Outlook, the company’s flagship publication. He has an MBA in Finance from Fordham University.

Read More

Forward Air (FWRD)

Sell: Forward Air (FWRD) From The Periscope Report Updated from Investment Digest 769, May 20, 2015 We are downgrading Forward Air (FWRD) to a SELL after it missed our earnings estimate. Management provided guidance for this quarter with revenue growth of 1% - 5% last...
Read More

Aegion Corporation (AEGN)

This leader in infrastructure protection and maintenance beat earnings estimates by four cents last quarter, and analysts are forecasting the company to grow at a more than 20% rate for next year. Aegion Corporation (AEGN) From The Periscope Report We always recommend companies that provide product...
Read More

Xenoport (XNPT)

Analysts are forecasting triple-digit growth for this biopharma company this year. Our other two recommendations today are sells on stocks that aren’t fulfilling expectations. Buy: Xenoport (XNPT) From The Periscope Report Xenoport (XNPT) is a biopharmaceutical company that focuses on developing a portfolio of product for...
Read More

SurModics (SRDX)

This medical device company hammered last quarter’s earnings estimates, but its biggest growth is ahead. SurModics (SRDX) From The Periscope Report SurModics (SRDX) provides surface modification and In Vitro Diagnostic technologies to the healthcare industry. The Medical Device segment offers surface modification coating technologies to enhance deliverability,...
Read More

Vascular Solutions (VASC)

This medical device company beat analysts’ estimates by two cents last quarter. The company will report earnings on Thursday, January 21st at 3:30pm CST, currently estimated at $0.27 per share. Vascular Solutions (VASC) From The Periscope Report Our top stock pick for 2016 is Vascular (VASC),...
Read More

TRC Companies (TRR)

This engineering and consulting business has just agreed to acquire the$209 million Professional Services business segment of Willbros Group (WG) for $130 million in an all-cash transaction, expected to close during the second quarter of TRC's fiscal 2016. The transaction is forecast to accretive...
Read More